RAPP Stock Summary and Trading Ideas (Rapport Therapeutics | NASDAQ:RAPP)

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Rapport Therapeutics trades on the NASDAQ stock market under the symbol RAPP.

As of December 13, 2024, RAPP stock price declined to $18.77 with 139,890 million shares trading.

RAPP has a beta of 2.61, meaning it tends to be more sensitive to market movements. RAPP has a correlation of 0.22 to the broad based SPY ETF.

RAPP has a market cap of $686.54 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that RAPP belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWO.

RAPP support price is $17.94 and resistance is $20.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RAPP shares will trade within this expected range on the day.